Brian Reed: Eliza, rough week or good week — actually, doesn't matter, I have something that'll wake you up either way.
Eliza Ward: Hand it over.
Brian Reed: Picture Doug Kass in April 2026. Cannabis has just run on rescheduling optimism, he decides the rally's overdone, liquidates most of his positions. Fine, disciplined, makes sense. Now jump to June — same Doug Kass is aggressively re-entering the exact same sector, supersizing into the AdvisorShares Pure US Cannabis ETF and selected multi-state operators. Less than two months.
Eliza Ward: Hold on — what happened in those two months that he wasn't already accounting for in April?
Brian Reed: That's the thing. I've gone back through the sources and they don't say. There's no named catalyst — no DEA announcement, no new data drop. He's citing 4x upside potential as the rationale, but that framing was available in April too, presumably.
Eliza Ward: So either he thinks the sector over-corrected after he sold — or the thesis shifted in a way the reporting just didn't capture.
Brian Reed: Yeah, and separating those two is actually the whole episode, I think. Because one of them is a trader catching a dip and one of them is a guy doubling down on a narrative he already believed.
Eliza Ward: And they look identical from the outside.
Brian Reed: And identical from the outside — but here's what actually breaks the clean version. Kass re-entered in June. The DEA hearing didn't even finish until July 15th.
Eliza Ward: Wait — he bought back in before the hearing concluded?
Brian Reed: Before it concluded, yeah. Eleven hearing days, wrapped July 15th. The presiding DEA Administrative Law Judge still hasn't written a recommendation. After that, the DEA Administrator rules. No timeline on either. So Kass re-entered on a process that, at the time, had no finish line visible.
Eliza Ward: Okay, let me just — for anyone who thinks Schedule III means legal cannabis, it doesn't. Think of it like a prescription reclassification. You're moving cannabis from 'zero accepted medical use, maximum risk' to 'has some accepted medical purpose.' That's it. It does not make it federally legal. It changes the government's risk category.
Brian Reed: And the 280E tax burden — the part where cannabis operators can't deduct rent or payroll like a normal company — the assumption is rescheduling kills that. But is that actually, like, confirmed mechanically?
Eliza Ward: Section 280E is a separate tax code provision. Rescheduling doesn't automatically remove it — that needs either the IRS to re-interpret or Congress to act. Nobody in the sourcing actually walks through how that happens. It's assumed.
Brian Reed: Right — and then layer in what Vicente LLP flagged. The opposition witnesses at those 11 hearing days weren't just making arguments. They were building an appellate record. Specific weaknesses in the government's analysis, disputed assumptions, omissions. The moment a final rule lands, those parties have a lawsuit ready.
Eliza Ward: So Trump's December 2025 executive order — directing the DOJ to finish this — that's a real political tailwind. But it doesn't shorten the legal obstacle course waiting at the end.
Brian Reed: The political will is there, the legal exposure is also there. And the thing to watch now — does the ALJ recommendation land before that litigation clock starts, and does it land fast enough that the trade Kass made in June still makes sense?
Eliza Ward: And that's the part worth sitting with — because the whole 4x thesis doesn't actually run through rescheduling. It runs through 280E. That's where the real money is.
Brian Reed: Right, so — let me try to make this concrete. Multi-state operators right now can't deduct rent. Can't deduct payroll. Can't take normal cost-of-goods deductions beyond direct production. 280E applies because cannabis is still a Schedule I substance federally. So these companies are paying tax on something close to gross revenue, not profit. The effective tax rate lands way above any normal corporation.
Eliza Ward: Wait — tax on revenue, not profit?
Brian Reed: Essentially, yeah. Which is why eliminating 280E isn't incremental — it's structural. The cash flow transformation for MSOs would be immediate and large. That's the engine under Kass's thesis.
Eliza Ward: Okay but does Schedule III automatically kill 280E? Because the sourcing I've seen doesn't actually confirm that. Rescheduling and 280E relief, they're not the same action.
Brian Reed: And I — yeah, I have to be honest that the sourcing doesn't settle it. You'd need either the IRS to re-interpret 280E as no longer applicable, or Congress to explicitly repeal it. Those are two different clocks with two different political problems. The thesis kind of... assumes the gap closes. It doesn't show you how.
Eliza Ward: Which is wild, because a cannabis lender — someone who's committed five hundred and fifty million dollars to this sector — said publicly in August 2026 that the opportunity is greater now than it was in 2019. Not equal. Greater.
Brian Reed: Five hundred fifty million — and saying the upside is bigger now. That means institutional capital is reading the 280E relief as real enough to price it in, even with the mechanism unsettled.
Eliza Ward: And whether the uplistings and M&A wave that come after rescheduling are still catalysts — or whether they've already been baked into the price by the time a final rule actually lands — that's uncomfortable for the 4x math.
Brian Reed: But uplistings aren't waiting for a final rule anymore. Trulieve already went public. M&A is already moving. So the question isn't whether those tailwinds exist. It's whether they've already done their work on the price.
Eliza Ward: Right — that's the chicken-and-egg.
Brian Reed: Cannabis stocks are still on over-the-counter markets or smaller exchanges — federal illegality is why. Rescheduling is the supposed unlock for NYSE or Nasdaq uplistings. Broader investor base, better liquidity, possible valuation re-rate. That's real. But if the market already believes rescheduling happens — and MSOS moved 30% from June when Kass re-entered — then the uplisting premium is maybe already in the price before a single stock actually uplistings.
Eliza Ward: Wait, so the catalyst lands and the stock... doesn't move?
Brian Reed: Or it moves less than the 4x math requires. Which is — I mean, that's the actual risk nobody's putting a number on. Virginia and Texas are named as near-term battlegrounds right now, mid-2026, independent of federal rescheduling. Demand catalysts that don't need the DEA to finish anything. So if those are already visible to the market too—
Eliza Ward: —then Kass's 4x is actually smaller than advertised. Some of it's already spent.
Brian Reed: Unless — and this is where that $550 million lender quote actually cuts the other way — unless institutional capital is saying the market hasn't fully priced it. They committed five-fifty to this sector and said publicly in August 2026 the opportunity is greater than 2019. That's not someone who thinks they're late.
Eliza Ward: Or it means the smart money moved and the retail side hasn't caught up yet — which is actually the more uncomfortable read.
Brian Reed: So which version is Kass buying? The one where the catalysts haven't priced in yet? Or the one where they have, and he just thinks momentum carries it the rest of the way? Because those require completely different exit strategies, and the sourcing doesn't tell us which one he's running.
Eliza Ward: That's actually where I keep getting stuck. Kass sold in April, bought in June — and we genuinely don't know what changed. Not a knock on the trade. Just the honest shape of it.
Brian Reed: Yeah. And when you lay it all out — the ALJ still has to write a recommendation, the DEA Administrator still has to rule, no timeline on either, then a probable court challenge the minute a final rule drops, then the 280E question that nobody's actually closed mechanically, then uplistings, then the consolidation wave — I mean, all of that has to land in sequence, in the right order, before the momentum that's already running through MSOS exhausts itself. That's... that's a lot of dominoes.
Eliza Ward: And we started this with Doug Kass deciding a rally was overdone. Now we're ending with him betting that a whole cascade of federal actions lands on time. Same guy, same sector, less than two months apart.
Brian Reed: That's the trade. Not rescheduling — the timing of rescheduling.
Eliza Ward: Good one to sit with.
